Leishmaniases are infections caused by Leishmania parasites and transmitted through the bite of infected female Phlebotomus (Old World) and Lutzomyia (New World) sandflies. The disease disproportionately affects marginalized communities with limited healthcare access. With no approved human vaccines available, leishmaniasis treatment and prevention depend heavily on chemotherapeutics that face growing drug resistance challenges alongside toxicity concerns. The development of safe, effective and affordable vaccines against human leishmaniasis remains a global health priority for disease control and elimination, mostly in resource-limited settings. This review synthesizes progress in leishmaniasis vaccine platforms including live-attenuated parasites, whole-killed parasites, DNA, protein subunit, peptide-based and chimeric/multiepitope vaccines and their homogenous and heterogenous efficacy. Live-attenuated and whole-parasite vaccines have been accounted to elicit robust cellular immunity but pose safety risks, particularly in immunocompromised hosts. While both second- and third-generation vaccines exemplified by LEISH-F1/F3 polyproteins, elicit strong Th1-biased T cell responses in preclinical models, their efficacy in humans remains limited. However, the highlighted collective efforts are pivotal in steering the rational development of future research using various formulations for multiple management of leishmaniasis through cross-protection. Furthermore, emerging strategies including mRNA platforms, nanoparticle delivery, reverse vaccinology, and immunoinformatics offer promising avenues for accelerating vaccine discovery and advancing the development of novel and effective human vaccines.
6 December 2023 in Microbes, Infection and Chemotherapy
Background: Subclinical mastitis, a disease that is economically important to dairy cows, affects milk production. Management of udder health is an essential element in the process of safe milk production. Consumption of milk with a high somatic cell count (SCC) may also pose a health risk to humans. Objectives. We aimed to evaluate the SCC method for the detection of SCM in dairy cows and to assess farmers’ knowledge, attitudes, and practices towards mastitis detection and control. Methods. A cross-sectional study was conducted to evaluate the current status of subclinical mastitis (SCM) in lactating dairy cows. The research work was also designed to assess farmers’ knowledge, attitudes, and practices about bovine mastitis. A total of 320 milk samples from 80 lactating cows were collected for physical examination and tested for subclinical mastitis using SCC. Results. Out of 80 lactating cows examined, 53 (66%, 95% CI: 55-76%) cows were diagnosed with subclinical mastitis. The average cow level SCC per ml of milk was 503101. According to the farmers’ self-report, 100% of farms practiced hand milking and 100% of milkmen washed their hands before milking. The majority of farms (90%) had brick floors. Most of the farmers (70%) knew about screening for subclinical mastitis. However, they never performed screening to detect subclinical mastitis. Conclusion. The high prevalence of SCM in dairy raised significant concerns about farm management, personal hygiene and biosecurity practices. Further study is needed to identify the etiologies of SCM and its associated risk factors.